A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

Clinical Trial ID NCT00027352

PubWeight™ 112.12‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00027352

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 22.76
2 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
3 Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008 13.72
4 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008 6.73
5 Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000 6.49
6 Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008 3.68
7 Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008 3.35
8 Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008 2.93
9 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008 2.72
10 Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011 2.21
11 Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009 2.20
12 AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000 2.13
13 Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008 2.06
14 Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000 1.99
15 Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009 1.96
16 Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009 1.66
17 Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008 1.34
18 Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014 1.26
19 Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009 1.26
20 Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008 1.21
21 Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012 1.16
22 Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000 1.10
23 Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials. Clin Trials 2016 1.06
24 HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc 2013 1.04
25 The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr 2008 1.04
26 Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. J Bone Miner Res 2013 1.03
27 Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011 1.01
28 Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS 2008 1.00
29 Factors Associated With Plasma IL-6 Levels During HIV Infection. J Infect Dis 2015 0.95
30 Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010 0.92
31 N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS 2011 0.91
32 Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 2013 0.90
33 Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS One 2016 0.89
34 Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr 2010 0.89
35 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 2010 0.89
36 Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses 2014 0.87
37 HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012 0.86
38 Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One 2013 0.86
39 Factors associated with D-dimer levels in HIV-infected individuals. PLoS One 2014 0.84
40 Platelet count kinetics following interruption of antiretroviral treatment. AIDS 2013 0.83
41 Haemoglobin and anaemia in the SMART study. Antivir Ther 2011 0.82
42 Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis 2016 0.82
43 Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002 0.82
44 Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). Am J Cardiol 2012 0.81
45 Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS 2015 0.79
46 Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection. Am J Cardiol 2012 0.77
47 Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS One 2015 0.75
48 Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications. Nutrients 2015 0.75
Next 100